IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer

Background Doublet combination therapies targeting immune checkpoints have shown promising efficacy in patients with advanced solid tumors, but it is unknown if rational triplet combinations will be well tolerated and associated with improved antitumor activity. The objective of this trial was to de...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Wei Guo, Manish R Patel, Nashat Gabrail, Jordi Rodon, Erika Hamilton, Timothy A Yap, Meghan Duncan, Alberto Bessudo, Jasgit Sachdev, Lena Evilevitch, Sujatha Kumar, Sharon Lu, Bruce J Dezube
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	BMJ Publishing Group 2022-03-01
Seri Bilgileri:	Journal for ImmunoTherapy of Cancer
Online Erişim:	https://jitc.bmj.com/content/10/3/e003924.full
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!